- Home
- Publications
- Publication Search
- Publication Details
Title
The role of the endocannabinoid system in islet biology
Authors
Keywords
-
Journal
Current Opinion in Endocrinology Diabetes and Obesity
Volume 18, Issue 2, Pages 153-158
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2011-02-11
DOI
10.1097/med.0b013e32834455a8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression and function of cannabinoid receptors in mouse islets
- (2011) Chen Li et al. Islets
- Cannabinoid Receptors are Coupled to Stimulation of Insulin Secretion from Mouse MIN6 β-cells
- (2010) Chen Li et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Effects of in vitro antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle
- (2010) K. A. Lindborg et al. DIABETES OBESITY & METABOLISM
- Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity
- (2010) Joseph Tam et al. JOURNAL OF CLINICAL INVESTIGATION
- Signaling diversity of PKA achieved via a Ca2+-cAMP-PKA oscillatory circuit
- (2010) Qiang Ni et al. Nature Chemical Biology
- Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression
- (2009) Fabrício A. Moreira et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders
- (2009) André J. Scheen et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- The cannabinoid CB1 receptor is expressed in pancreatic δ-cells
- (2008) William G. Tharp et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients: Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes
- (2008) J. Rosenstock et al. DIABETES CARE
- Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program
- (2008) L. Van Gaal et al. DIABETES CARE
- Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle
- (2008) K. Eckardt et al. DIABETOLOGIA
- Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice
- (2008) Nigel Irwin et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice
- (2008) Douglas Osei-Hyiaman et al. JOURNAL OF CLINICAL INVESTIGATION
- Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal!
- (2008) Natasha L. Grimsey et al. JOURNAL OF NEUROSCIENCE METHODS
- The CB1 Endocannabinoid System Modulates Adipocyte Insulin Sensitivity
- (2008) Roja Motaghedi et al. Obesity
- Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a High-fat Diet
- (2008) Katarzyna M. Starowicz et al. Obesity
- Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?
- (2008) George Kunos et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet β-cells via CB1 receptors
- (2007) Masanori Nakata et al. REGULATORY PEPTIDES
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now